advertisement
11.4 Prostaglandins (101)
Showing records 1 to 25
Display all abstracts in classification 11.4 Prostaglandins
Search within classification 11.4 Prostaglandins67331 Effect of Switching From Latanoprost to Bimatoprost in Primary Open-Angle Glaucoma Patients Who Experienced Intraocular Pressure Elevation During Treatment
Germano RA
Journal of Glaucoma 2016; 25: e359-e366
67126 ABCB1 variants confer susceptibility to primary open-angle glaucoma and predict individual differences to latanoprost treatment
Liu H
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2016; 80: 115-120
67517 A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
Stevens A
Clinical Ophthalmology 2016; 10: 635-641
67184 Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials
Uusitalo H
Clinical Ophthalmology 2016; 10: 445-454
66741 Periocular mexametric melanin and erythema indexes in adult glaucoma patients treated with topical prostaglandin analogs
Duman N
Cutaneous and Ocular Toxicology 2016; 0: 1-3
66817 Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma
Naito T
Advances in Therapy 2016; 33: 435-446
66745 Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial
Stalmans I
Graefe's Archive for Clinical and Experimental Ophthalmology 2016; 254: 1151-1158
67570 Prostaglandins in the eye: Function, expression, and roles in glaucoma
Doucette LP
Ophthalmic Genetics 2016; 0: 1-9
67284 Bimatoprost, latanoprost, and tafluprost induce differential expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases
Yamada H
BMC Ophthalmology 2016; 16: 26
67159 Activation of Prostaglandin FP and EP2 Receptors Differently Modulates Myofibroblast Transition in a Model of Adult Primary Human Trabecular Meshwork Cells
Kalouche G
Investigative Ophthalmology and Visual Science 2016; 57: 1816-1825
67320 A Randomized Trial of Fixed-Dose Combination Brinzolamide 1%/Brimonidine 0.2% as Adjunctive Therapy to Travoprost 0.004
Feldman RM
American Journal of Ophthalmology 2016; 165: 188-197
66621 Effects of topical travoprost 0.004% on intraocular pressure and corneal biomechanical properties in an animal model
Lazcano-Gomez G
Digital journal of ophthalmology : DJO / sponsored by Massachusetts Eye and Ear Infirmary 2016; 22: 1-5
67163 Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost
Imasawa M
Open Ophthalmology Journal 2016; 10: 94-102
67443 Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population
Perera SA
Clinical Ophthalmology 2016; 10: 757-764
67153 Thermosensitive chitosan-based hydrogel as a topical ocular drug delivery system of latanoprost for glaucoma treatment
Cheng YH
Carbohydrate polymers 2016; 144: 390-399
66833 Association between glaucoma eye drops and hyperemia
Yanagi M
Japanese Journal of Ophthalmology 2016; 60: 72-77
66794 Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study
Weinreb RN; Scassellati Sforzolini B
Ophthalmology 2016; 123: 965-973
66741 Periocular mexametric melanin and erythema indexes in adult glaucoma patients treated with topical prostaglandin analogs
Duman R
Cutaneous and Ocular Toxicology 2016; 0: 1-3
66817 Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma
Okuma S
Advances in Therapy 2016; 33: 435-446
67184 Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials
Egorov E
Clinical Ophthalmology 2016; 10: 445-454
67517 A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
Iliev ME
Clinical Ophthalmology 2016; 10: 635-641
67159 Activation of Prostaglandin FP and EP2 Receptors Differently Modulates Myofibroblast Transition in a Model of Adult Primary Human Trabecular Meshwork Cells
Beguier F
Investigative Ophthalmology and Visual Science 2016; 57: 1816-1825
67126 ABCB1 variants confer susceptibility to primary open-angle glaucoma and predict individual differences to latanoprost treatment
Yang ZK
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2016; 80: 115-120
67320 A Randomized Trial of Fixed-Dose Combination Brinzolamide 1%/Brimonidine 0.2% as Adjunctive Therapy to Travoprost 0.004
Katz G
American Journal of Ophthalmology 2016; 165: 188-197
66621 Effects of topical travoprost 0.004% on intraocular pressure and corneal biomechanical properties in an animal model
Ancona-Lezama D
Digital journal of ophthalmology : DJO / sponsored by Massachusetts Eye and Ear Infirmary 2016; 22: 1-5
